title: Detection of the Epstein-Barr virus and DNA-topoisomerase II- α in recurrent and nonrecurrent giant cell lesion of the jawbones.
abstract: The aims of this study were to determine whether the expression of Topo II-α correlates with presence of EBV in giant cell lesion of the jawbones and whether it is predictive of clinical biologic behavior of these lesions. Paraffin-embedded tissues from 8 recurrent and 7 nonrecurrent cases of bony GCLs and 9 peripheral giant cell lesions (PGCLs) as a control group were assessed for the expression of EBV and Topo II-α using immunohistochemistry. The results showed positive staining for Topo II-α in mononuclear stromal cells (MSCs) and multinucleated giant cells (MGCs). Student t-test showed that mean Topo II-α labelling index (LI) in recurrent cases was significantly higher than that in non-recurrent cases (P = 0.0001). Moreover, Spearman's correlation coefficients method showed a significant correlation between DNA Topo II-α LI and both of gender and site in these lesions. Moderate EBV expression in relation to the highest Topo II-α LI was observed in two cases of GCT. It was concluded that high Topo II-α LIs could be identified as reliable predicators for the clinical behavior of GCLs. Moreover, EBV has no etiological role in the benign CGCLs in contrast to its role in the pathogenesis of GCTs.
authors: Faculty of Dentistry, Mansoura University, P.O. Box 40, Mansoura 35516, Egypt. zyadam@yahoo.com
authors: Manal M
authors: MM
authors: Zyada
authors: Nagla M
authors: NM
authors: Salama
mesh_terms: D000951:Antigens, Neoplasm / Q000235:genetics / Q000378:metabolism*; D001706:Biopsy; D001847:Bone Diseases / Q000378:metabolism / Q000473:pathology*; D002467:Cell Nucleus / Q000378:metabolism; D003593:Cytoplasm / Q000378:metabolism; D004247:DNA / Q000378:metabolism*; D004250:DNA Topoisomerases, Type II / Q000235:genetics / Q000378:metabolism*; D004268:DNA-Binding Proteins / Q000235:genetics / Q000378:metabolism*; D015726:Giant Cells / Q000201:enzymology / Q000473:pathology* / Q000821:virology; D004854:Herpesvirus 4, Human / Q000302:isolation & purification / Q000472:pathogenicity; D006801:Humans; D007150:Immunohistochemistry; D007568:Jaw / Q000166:cytology / Q000473:pathology
chemical_list: D000951:Antigens, Neoplasm; D004268:DNA-Binding Proteins; D004247:DNA; D004250:DNA Topoisomerases, Type II
references: Arch Biochem Biophys. 2005 Sep 1;441(1):41-55
references: 16091284
references: Mod Pathol. 2000 Apr;13(4):396-400
references: 10786805
references: J Clin Invest. 1987 Feb;79(2):483-91
references: 3027126
references: J Oral Pathol Med. 1993 Sep;22(8):337-47
references: 8283399
references: J Cancer Res Clin Oncol. 2001 Aug;127(8):467-74
references: 11501745
references: J Oral Pathol Med. 2004 Mar;33(3):170-6
references: 15128059
references: Biochemistry. 1999 Aug 17;38(33):10793-800
references: 10451375
references: Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2006 Mar;101(3):346-54
references: 16504869
references: J Cell Biol. 1985 May;100(5):1706-15
references: 2985625
references: J Clin Pathol. 1992 May;45(5):398-404
references: 1597517
references: J Oral Pathol Med. 1999 Feb;28(2):54-8
references: 9950250
references: J Neurosurg. 1999 Sep;91(3):477-82
references: 10470824
references: Clin Orthop Relat Res. 2003 Nov;(416):278-84
references: 14646771
references: Annu Rev Biochem. 1996;65:635-92
references: 8811192
references: Mod Pathol. 1997 Sep;10(9):901-7
references: 9310953
references: Cancer Res. 1992 Jan 1;52(1):231-4
references: 1309226
references: J Oral Pathol Med. 1993 Jan;22(1):12-7
references: 8380451
references: N Engl J Med. 2000 Aug 17;343(7):481-92
references: 10944566
references: N Engl J Med. 1985 Dec 19;313(25):1564-71
references: 2999595